Advertisement

Molecular and Cellular Biochemistry

, Volume 185, Issue 1–2, pp 85–94 | Cite as

The salubrious effect of tamaxifen on serum marker enzymes, glycoproteins, and lysosomal enzymes level in breast cancer women

  • M. Thangaraju
  • J. Rameshbabu
  • H. Vasavi
  • S. Ilanchezhian
  • R. Vinitha
  • P. Sachdanandam
Article

Abstract

Tumour markers correlate strongly with prognosis based on tumour burden and surgical resectability. If chemotherapy is extremely effective in certain stage of the disease, the sensitive marker may be of great use in monitoring disease response and drug treatment. Hence, this study was launched to evaluate the changes in tumour marker enzymes like lactate dehydrogenase (LDH), glumate oxaloacetate transaminase (SGOT), glutamate pyruvate transaminase (SGPT), alkaline phosphatase, and acid phosphatase in before and after 3 and 6 months tamoxifen treated breast cancer patients. In addition, the changes in serum glycoproteins viz., hexose, hexosamine, and sialic acid and lysosomal enzymes such as N-acetyl-beta-D-glucosaminidase, beta-D-galactosidase, and beta-D-glucuronidase were analysed in these patients. These values were compared with their age matched healthy control subjects. At 6 months evaluation, the tamoxifen treated postmenopausal breast cancer women showed a statistically significant decreased (p < 0.001, 0.05 respectively) levels of LDH, SGOT, SGPT, alkaline and acid phosphatases than their baseline values. Similarly, the levels of hexose, hexosamine, and sialic acid and N-acetyl-beta-D-glucosaminidase, beta-D-galactosidase, and beta-D-glucuronidase were decreased significantly (p < 0.001 ) in tamoxifen received postmenopausal women. The result of this study suggested that tamoxifen potentially retard the metastasis of breast cancer as well as the bone demineralisation in postmenopausal breast cancer women. Thus, tamoxifen may also have its antitumour activity through its beneficial effects on tumour marker enzymes and serum proteins in breast cancer women.

tamoxifen breast cancer marker enzymes glycoproteins lysosomal enzymes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jordan VC: A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110: 507–517, 1993Google Scholar
  2. 2.
    Jordan VC: Overview from the international conference on long term tamoxifen therapy for breast cancer. J Natl Cancer Inst 84: 231–234, 1992Google Scholar
  3. 3.
    Thangaraju M, Kumar K, Gandhirajan R, Sachdanandam P: Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer 73: 659–663, 1994Google Scholar
  4. 4.
    Dristrian AM, Schwartz MK, Greenberg EJ, et al.: Effect of tamoxifen on serum cholesterol and lipoproteins during chemotherapy. Clin Chim Acta 223: 43–52, 1993Google Scholar
  5. 5.
    McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen trial. Br Med J 303: 435–437, 1991Google Scholar
  6. 6.
    Bruning PF, Bonfrer JMG, Hart AAM, et al.: Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 58: 497–499, 1988Google Scholar
  7. 7.
    Love RR, Mazess RB, Barden HS, et al.: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852–856, 1992Google Scholar
  8. 8.
    Lemer LJ, Jordan VC: Development of antiestrogen and their use in breast cancer. Cancer Res 50: 4177–4189, 1990Google Scholar
  9. 9.
    Coezy EJ, Borgama L, Ruchefort M: Tamoxifen and metabolises in MCF-7 cells: Correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42: 317–321, 1982Google Scholar
  10. 10.
    Reddel RR, Murphy LC, Hall RE, Sutherland RL: Differential sensitivity of human breast cancer cell line to the growth-inhibitory effects of tamoxifen. Cancer Res 45: 1525–1531, 1985Google Scholar
  11. 11.
    O'Brain CA, Liskam RM, Solomon DH, Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer Res 45: 2462–2465, 1985Google Scholar
  12. 12.
    Lam HY: Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiestrase. Biochim Biophys Res Commun 118: 27–32, 1984Google Scholar
  13. 13.
    Thangaraju M: Biochemical studies on the antitumour activity of tamoxifen in breast cancer women with special reference to plasma lipids and lipid peroxides. PhD thesis, University of Madras, India 171–173, 1995Google Scholar
  14. 14.
    Schwartz MK: Enzymes as prognostic markers and therapeutic indicator in patients with cancer. Clini Chimi Acta 206: 77–82, 1992Google Scholar
  15. 15.
    Nachbar MS, Oppenheim JD, Aull F: Cell surface contributions to the malignant process. Am J Med Sci 268: 122–138, 1974Google Scholar
  16. 16.
    Pederson PL: Enzymology ultrastructure and energies of mitochondria from three morris hepatoma of widely differentiated growth rates. Gann Monograph on Cancer Res 13: 251–165, 1972Google Scholar
  17. 17.
    Buck CA, Fuhrer JP, Soslan G: Membrane glycoproteins sub-cellular fractions of control and virus transformer cells. J Biol Chem 249: 1541–1550, 1974Google Scholar
  18. 18.
    Bossmann HB, Hall TC: Enzyme activity in invasive tumours of human breast and colon. Proc Natl Acad Sci, USA 71: 1833–1837, 1974Google Scholar
  19. 19.
    Bossmann HB, Lockwood T, Morgan HR: Surface biochemical changes accompanying primary infection with Rous Sarcoma Virus II. Proteolytic and glycosidase activity and sublethal autolysis. Exp Cell Res 83: 25–30, 1974Google Scholar
  20. 20.
    Roth S, McGuire EJ, Rosemann S: Evidence for cell surface glycosyltransferases: their potential role in cellular recognition. J Biol Chem 51: 536–547, 1971Google Scholar
  21. 21.
    Bossmann HB: Glycoprotein degradation: Glycosidases in fibroblasts transformed by oncogenic virus. Exp Cell Res 54: 217–221, 1969Google Scholar
  22. 22.
    Ilanchezhian S, Thangaraju M, Sachdanandam P: Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status. Cancer Biochem Biophys 15: 1–8, 1995Google Scholar
  23. 23.
    Thangaraju M, Vijayalakshmi T, Sachdanandam P: Effect of tamoxifen on lipid peroxide and antioxidative system in postmenopausal women with breast cancer. Cancer 73: 659–663, 1995Google Scholar
  24. 24.
    Thangaraju M, Ilanchezhian S, Ezhilarasi R, Sachdanandam P: Lipid peroxidation and antioxidant enzyme levels in tamoxifen-treated breast cancer women in relation to the menopausal status of the patients. Med Sci Res 21: 721–724, 1993Google Scholar
  25. 25.
    Thangaraju M, Ezhilarasi R, Sachdanandam P: Effect of tamoxifen on erythrocyte membrane lipids, lipid peroxides and antioxidative enzymes in breast cancer women. Cancer Biochem Biophy 14: 297–302, 1995Google Scholar
  26. 26.
    Dubowski KM: An O-toluidine method for body fluid glucose determinations. Clin Chem 8: 215–235, 1962Google Scholar
  27. 27.
    Sasaki T, Matsuis S: Effect of acetic acid concentration on the colour reaction in the O-toluidine-boric acid method of the blood glucose determination. Rinsho-Kagaku 1: 346–353, 1972Google Scholar
  28. 28.
    Drabkin DL, Austin JN: Spectrophotometric studies, spectrophotometric constants for common haemoglobin derivatives in human, dog, and rabbit blood. J Biol Chem 98: 719–733, 1932Google Scholar
  29. 29.
    Lowry OH, Rosebrough NJ, Farr AL, Randall R: Protein measurement with Folin's phenol reagent. J Biol Chem 193: 265–275, 1952Google Scholar
  30. 30.
    King F: Colorimetric determination of serum enzymes. In: Practical Clinical Enzymology. Van Nostrand, London 1: 247–283, 1952Google Scholar
  31. 31.
    Moog F: Acid and alkaline phosphatases in chick embryo. J Cell Comp Physiol 28: 197–208, 1946Google Scholar
  32. 32.
    Tettamanti G, Banali F, Marchesini S, Zambothi Y: A new procedure for the extraction, purification, and fractionation of brain gangliosides. Biochem Biophys Acta 267: 160–170, 1983Google Scholar
  33. 33.
    Niebes P: Determination of enzyme and degradation products of GAG metabolism in the serum of healthy and various subjects. Clin Chim Acta 42: 399–408, 1972Google Scholar
  34. 34.
    Wagner WD: More sensitive assay discriminating galactosamine and glucosamine in mixtures. Anal biochem 94: 394–397, 1979Google Scholar
  35. 35.
    Warren L: The thiobarbituric acid assay of sialic acid. J Biol Chem 234: 1971–1975, 1959Google Scholar
  36. 36.
    Hultberg B, Lindsten J, Siobtad S: Molecular forms and activities of glycosidases in amniotic fluid cells. Biochem J 155: 599–605, 1976Google Scholar
  37. 37.
    Meisler MH, Fry JB, Palyan K: Beta-galactosidase from human liver. Fed Proc Fed Ame Soc Exp Biol 30: 1118–1121, 1971Google Scholar
  38. 38.
    Kawaii Y, Anno K: Mucopolysaccharide degrading enzymes from the liver of the squill. Ommastrephes Sloanifacifieus. Biochem Biophys Acta 242: 428–436, 1971Google Scholar
  39. 39.
    Greengard O, Head JF, Goldenberg SL, Krishchem PA: Enzyme pathology and the histologic categorisation of human lung tumours. The continue qualitative biochemical indices of neoplasticity. Cancer 49: 46–48, 1982Google Scholar
  40. 40.
    Hilt R, Fledsten ML, Gibson SL, Savio ED: A logistic model based enzyme activities for the prediction of response of breast cancer patients to chemotherapy. Cancer 50: 1734–1738, 1982Google Scholar
  41. 41.
    Schwartz MK: Enzymes in cancer. Clin Chem 19: 10–22, 1973Google Scholar
  42. 42.
    Pui CH, Dodge PK, Dahl GV, et al.: Serum lactic dehydrogenase levels has prognostic value in childhood acute lymphoblastic leukemia. Blood 66: 778–782, 1985Google Scholar
  43. 43.
    Ferraris AM, Giuntini P, Gaetani GF: Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood 54: 928–932, 1979Google Scholar
  44. 44.
    Finck S, Giuliano AK, Morton DL: LDH and melanoma. Cancer 51: 840–843, 1983Google Scholar
  45. 45.
    Neville AM: Prognostic factors and primary breast cancer. Diag Oncol 1: 5363, 1991Google Scholar
  46. 46.
    Khan N, Tyagi SP, Salahuddain A: Diagnostic and prognostic significance of serum cholin-estrase and lactate dehydrogenase in breast cancer. Ind J Pathol Microbiol 34: 126–130, 1991Google Scholar
  47. 47.
    Kumar K: Plasma lipid alteration and related biochemical studies in mammary tumour. PhD Thesis, University of Madras, India. 1991, pp 127–135Google Scholar
  48. 48.
    Nano R, Roveta G, Rezzani R, Roadella L: Changes observed in lactate dehydro genase activity in fibro sarcoma bearing rats. Boll Soc Ital Sper 65: 273–278, 1989Google Scholar
  49. 49.
    Hisson JR, Bowden RT, Moore MR: Effects of progestins, estrogens, and antihormones on growth and lactate dehydrogenase in the human breast cancer cell line T47D. Endocrinol 125: 418–423, 1989Google Scholar
  50. 50.
    Nagai MA, Sonohara S, Brentani MM: Estrogen control of lactate dehydrogenase isoenzyme-5 in human breast cancer. Int J Cancer 41: 10–16, 1988Google Scholar
  51. 51.
    Tsai CL, Liu TK: Inhibition of estradiol-induced early osteoarthritic changes by tamoxifen. Life Sciences 50: 1943–1951, 1992Google Scholar
  52. 52.
    Jordan VC: Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications. Breast Cancer Res Treat 3: 573–586, 1983Google Scholar
  53. 53.
    Coleman RE, Rubens RD: Bone metastases and breast cancer. Cancer Treat Rev 12: 251–270, 1985Google Scholar
  54. 54.
    Gutman AB, Gutman EB: An acid phosphatase occuring in the serum of patients with metastasizing carcinoma of the prostatic gland. J Clin Invest 17: 473–478, 1938Google Scholar
  55. 55.
    Nguyen M, Bonneterre J, Hecquet B, et al.: Plasma acid and alkaline phosphatase in patients with breast cancer. Anticancer Res 11: 831–834, 1991Google Scholar
  56. 56.
    Desoize B, Veiler V, Pourny C, et al.: Isoenzymes of alkaline and acid phosphatases as bone metastasis marker in breast cancer patients. Anticancer Res 9: 1105–1110, 1989Google Scholar
  57. 57.
    DiLovenzo D, Gianni M, Savoldi GF, et al.: Progesterone induced the expression of alkaline phosphastase is associated with a secretory phenotype in T47D breast cancer cells. Biochem Biophys Res Comuni 192: 1066–1972, 1993Google Scholar
  58. 58.
    Love RR, Mazess RB, Barden HS, et al.: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852–856, 1992Google Scholar
  59. 59.
    Kapiler M: Cell surface shedding. The phenomenon with a possible significance. J Theor Biol 62: 253–261, 1976Google Scholar
  60. 60.
    Yogeswaran G: Cell surface glycolipids in malignant transformation. Adv Cancer Res 38: 289–350, 1983Google Scholar
  61. 61.
    Burridge K: Changes in cellular glycoproteins after transformation. Proc Natl Acad Sci 73: 4457–4461, 1976Google Scholar
  62. 62.
    Pearson JP, Pretlow TP, Bradlay EL, et al.: Beta-glucuronidase activity in prostatic carcinoma and benign prostatic hyperplasia. Cancer 64: 911–915, 1989Google Scholar
  63. 63.
    Bossmann HB, Bieber GF, Brown A, et al.: Biochemical parameters correlated with tumour cell implantation. Nature 246: 487–489, 1973Google Scholar
  64. 64.
    Severini G, Diana L, Giovannandrea RD, Tirelli C: A study of serum glycosideases in cancer. J Cancer Res Clin Oncol 121: 61–63, 1995Google Scholar
  65. 65.
    Adamo V, Altavilla G, Caristi M, et al.: Serum sialic acid are tumour marker in neoplastic disease. Mineral Med 76: 2067–2074, 1985Google Scholar
  66. 66.
    Potter VR: Biochemical perspectives in cancer research. Cancer Res 24: 1085–1098, 1964Google Scholar
  67. 67.
    Toimela T, Tahti H, Salminen L: Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and chloroquine. Ophtha Res 27: 150–153, 1995Google Scholar
  68. 68.
    Gotterdesen A, Christiansen C, Palshof T: The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 53: 853–857, 1984Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • M. Thangaraju
    • 2
  • J. Rameshbabu
    • 1
  • H. Vasavi
    • 1
  • S. Ilanchezhian
    • 1
  • R. Vinitha
    • 1
  • P. Sachdanandam
    • 1
  1. 1.Department of Medical Biochemistry, Dr.ALMP-GIBMSUniversity of Madras, Taramani Campus, MadrasTamilnaduIndia
  2. 2.Department of Medicine, Royal Victoria HospitalMcGill UniversityMontréalCanada

Personalised recommendations